Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients
Abstract The effect of the combination of atezolizumab and bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC) on pulmonary arterial hypertension (PAH) is unknown. Estimation of PAH by using computed tomography (CT) has recently been proposed. Thus, we aimed to estimate the effect of Atez/Bev...
Main Authors: | Takayuki Kondo, Kisako Fujiwara, Miyuki Nakagawa, Kentaro Fujimoto, Sae Yumita, Takamasa Ishino, Keita Ogawa, Terunao Iwanaga, Keisuke Koroki, Hiroaki Kanzaki, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Sadahisa Ogasawara, Shingo Nakamoto, Tetsuhiro Chiba, Jun Kato, Naoya Kato |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-07-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-38377-2 |
Similar Items
-
Potential of circulating receptor-interacting protein kinase 3 levels as a marker of acute liver injury
by: Takayuki Kondo, et al.
Published: (2023-08-01) -
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
by: Sae Yumita, et al.
Published: (2023-03-01) -
The efficacy of contrast-enhanced computed tomography on the management of gastroesophageal varices in patients with hepatocellular carcinoma
by: Takayuki Kondo, et al.
Published: (2022-12-01) -
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis
by: Hiroaki Kanzaki, et al.
Published: (2023-07-01) -
Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial
by: Masato Nakamura, et al.
Published: (2022-04-01)